MBE Wealth Management’s Aclaris Therapeutics ACRS Stock Holding History

MBE Wealth Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$52.6K	Buy	+10,000	New	+$57.1K	0.02%	173

Other funds holding ACRS

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

CRA Financial Services Northfield, New Jersey $904M AUM 20.1% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

MBE Wealth Management's ACRS Position: Q3 2026 in Review

MBE Wealth Management opened a new position in Aclaris Therapeutics (ACRS) in Q3 2026: 10,000 shares worth $52.6K. The stake represents 0.02% of the portfolio and ranks #173 among its holdings.

25 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

MBE Wealth Management held 10,000 shares of Aclaris Therapeutics worth $52.6K as of Q3 2026.
Aclaris Therapeutics was a new MBE Wealth Management position in Q3 2026.
Aclaris Therapeutics made up 0.02% of MBE Wealth Management's portfolio in Q3 2026, its #173 holding.
25 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on MBE Wealth Management's 13F filing for Q3 2026, filed 26 Oct 2026.